Adverse effects: one or more adverse events during 24 hours (only reported if occurred in ≥ 5% of people) · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes adverse effects: one or more adverse events during 24 hours (only… compared with PLACEBO/NIL (very low certainty).
1 finding from 1 review
Economic outcomes · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mental state: significant response or improvement in negative symptoms (PANSS negative subscale, high = worse) ‐ short term (12 weeks) · adults with schizophrenia
It is very uncertain whether noradrenaline reuptake inhibitors changes mental state: significant response or improvement in negative… compared with placebo (very low certainty).
1 finding from 1 review
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · adults with schizophrenia
1 finding from 1 review
Clinical global response: significant response or improvement in global status (CGI‐S, high = worse) ‐ short term (4 weeks) · adults with schizophrenia
It is very uncertain whether noradrenaline reuptake inhibitors changes clinical global response: significant response or improvement in… compared with placebo (very low certainty).
1 finding from 1 review
Cognitive functioning: significant response or improvement in cognitive functioning · adults with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cognitive function: average endpoint score** · adults with schizophrenia
1 finding from 1 review
QoL · adults with schizophrenia
1 finding from 1 review
Nausea · adults with schizophrenia
Noradrenaline reuptake inhibitors showed no clear difference in adverse effects: Nausea ‐ short term (2 to 12 weeks) compared with placebo (low certainty).
1 finding from 1 review
Mental state: 2a. Negative symptoms ‐ No clinical important improvement ‐ negative symptoms (SANS) · schizophrenia
It is very uncertain whether mirtazapine adjunct changes mental state: specific negative symptoms ‐ clinically important… compared with placebo adjunct (very low certainty).
1 finding from 1 review
Mental state: clinically important change in mental state · schizophrenia
It is very uncertain whether mirtazapine adjunct changes mental state: overall mental state ‐ clinically important change* compared with placebo adjunct (very low certainty).
1 finding from 1 review
Leaving the study early · schizophrenia
Mirtazapine adjunct showed no clear difference in leaving the study early for any reason compared with placebo adjunct (moderate certainty).
1 finding from 1 review
Clinical response: mean score/change in global state: mean CGI‐S score (high = poor) Medium term (12 weeks) · schizophrenia
1 finding from 1 review
Quality of life: clinically important change in quality of life · schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Service utilisation outcomes: hospital admission or days in hospital · schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effect/event: clinically important extrapyramidal adverse events ‐ akathisia (medium term) · schizophrenia
Mirtazapine adjunct may leads to lower adverse effects: extrapyramidal ‐ clinically important change… compared with placebo adjunct (low certainty).
1 finding from 1 review
Tranquillisation or asleep: sedation ‐ medium termNumber of participants sedated · psychosis‐induced aggression or agitation
It is very uncertain whether benzodiazepines changes tranquillisation or asleep: sedation ‐ medium termNumber of… compared with placebo (very low certainty).
1 finding from 1 review
Global state: no improvement ‐ medium termAs defined in each study · psychosis‐induced aggression or agitation
It is very uncertain whether benzodiazepines changes global state: no improvement ‐ medium termAs defined in each study compared with placebo (very low certainty).
1 finding from 1 review
Global impression ‐ need for additional medication ‐ medium term Number of participants requiring additional medication · psychosis‐induced aggression or agitation
It is very uncertain whether benzodiazepines changes global state: need for additional medication ‐ medium termNumber of… compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · psychosis‐induced aggression or agitation
It is very uncertain whether benzodiazepines changes adverse effects/events: extrapyramidal symptoms ‐ medium termNumber… compared with placebo (very low certainty).
1 finding from 1 review